Price increases and new drugs drive increased expenditures for multiple sclerosis

Journal of Managed Care Pharmacy

Volumn 16, Issue 9, 2010, Pages 713-717

  Schafer, Jeremy A ^a   Gunderson, Brent W ^b   Gleason, Patrick P ^b,c  

^a Prime Therapeutics LLC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; BETA1A INTERFERON; DALFAMPRIDINE; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; UNCLASSIFIED DRUG;

BRAIN DYSFUNCTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG APPROVAL; DRUG COST; EMERGENCY WARD; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH SURVEY; HUMAN; MEDICAID; MEDICARE; MULTIPLE SCLEROSIS; NOTE; OCCUPATIONAL THERAPY; PHYSIOTHERAPY; RELAPSE; SPEECH THERAPY;

EID: 78649500113     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2010.16.9.713     Document Type: Note

References (18)

1. Noseworthy J, Lucchinetti C, Rodriguez M, Weinshenker B. Multiple sclerosis. N Engl J Med. 2000;343(13):938-52.
2. Ryan M. Multiple Sclerosis. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, ed. Pharmacotherapy A Pathophysiologic Approach. New York, NY: McGraw Hill; 2008:431-441.
3. Pope GC, Urato CJ, Kulas ED, Kronick R, Gilmer T. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology. 2002;58(1):37-43.
4. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66(11):1696-702.
5. Asche CV, Singer ME, Jhaveri M, Chung H, Miller A. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm. 2010;16(9):703-12. Available at: http://www.amcp.org/data/jmcp/703-712.pdf.
6. Kunze AM, Gunderson BW, Gleason PP, Heaton AH, Johnson SV. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs-pharmacy and medical benefit spending from 2004 through 2007. J Manag Care Pharm. 2007;13(9):799-806. Available at: http://www.amcp.org/data/jmcp/JMCPMaga_N-D%2007_799-806.pdf.
7. Internal data. Prime Therapeutics. Eagan, Minnesota. Pharmacy and medical claims data for approximately 9.0 million members, dates of service from January 1, 2006, through September 30, 2010.
8. Goldberg LD, Edwards NC, Fincher C, Doan QV, AL-Sabbagh A, Meletiche DM. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm. 2009;15(7):543-55. Available at: http://www.amcp.org/data/jmcp/543-555.pdf.
9. Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsingremitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007;13(3):245-61. Available at: http://www. amcp.org/data/jmcp/245-61.pdf.
10. Ampyra (dalfampridine). Acorda. January 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf. Accessed October 29, 2010.
11. Wolters Kluwer Health. Medi-Span database. Accessed October 11, 2010.
12. U.S. Food and Drug Administration. FDA approves first oral drug to reduce MS relapses. September 22, 2010. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226755.htm. Accessed October 29, 2010.
13. Association of British Neurologists. Revised (2009) Association of British Neurologists' guidelines for prescribing in multiple sclerosis. Available at: http://www.theabn.org/abn/userfiles/file/ABN_MS_Guidelines_2009_ Final(1).pdf. Accessed October 27, 2010.
14. Pohl D, Waubant E, Banwell B, et al. Treatment of pediatric multiple sclerosis and variants. Neurology. 2007;68(16 suppl 2):S54-S65.
15. Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol. 2008;255(10):1449-63.
16. Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373(9665):732-38.
17. U.S. Food and Drug Administration. NDA 22-250: fampridine AC backgrounder. September 16, 2009. Available at: http://www.fda. gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM185663.pdf. Accessed October 27, 2010.
18. Gleason PP, Starner CI, Gunderson BW, Schafer JA, Sarran HS. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm. 2009;15(8):648-58. Available at: http://www.amcp.org/data/jmcp/648-658.pdf.